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Abstract
Sickle cell anemia, an inherited disorder, causes red blood cells to contort into a disk or
sickled shape becoming hard and sticky and obstructing blood flow. As the most common
hemoglobinopathy, over 100,000 Americans in the US are affected by sickle cell disease. Sickle
cell anemia is an inheritance of the abnormal sickle cell gene genetically transferred from both
parents. Sickle cell anemia can be easily diagnosed in DNA through a blood test or genetic
screening. With a 1 in 4 chance of inheriting copies of the sickle cell gene from both parents if
both biological parents are carriers, the cause of sickle cell anemia is due to a single amino acid
mutation due to a nucleotide polymorphism or variation typically due to a protein substitution.
Individuals with sickle cell anemia may experience signs and symptoms while they are only a
few months old. Common signs or symptoms related to this disease are severe headaches,
unexplained numbness, confusion, or dizziness. The pathophysiology of sickle cell anemia or
SCA relies on the genetics of endometrial dysfunction, HbS polymerization, sterile inflammation
and vaso-occlusion. For inpatient hospital visits, sickle cell disease diagnosis was recorded in
about 1.7% of whites, 3.9% of Hispanics and 87.5% of blacks (Fingar et al., 2019). Sickle cell
anemia life expectancy is two decades shorter in adults compared to children and young adults.
Several complications may arise with those infected by SCA, such areas include gallstones,
kidney disease, splenic sequestration and may even cause blindness. There are a few
management strategies from vitamin intake to bone marrow or stem cell transplant to subdue
pain and complications of sickle cell anemia. Sickle cell anemia is a costly, long term health
condition that commonly affects minorities. The low income community makes up
approximately 92.5% of inpatient hospital visits for patients diagnosed with SCA. Because sickle
cell anemia is a lifelong disease, complications that affect the nervous system of those with SCA
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may progress with age further exacerbating any symptoms associated with this disease. Sickle
cell anemia has been known to lead to a decrease in cognitive attainment, strokes, and even
neurological issues such as neuropathy that can result in paralysis. These reported neuropathies
occurring in patients with sickle cell disease; are specific neuropathies like peripheral
neuropathy, mental & mandibular nerve neuropathy and mononeuropathy multiple. Studies on
cognitive activity provide evidence that individuals with SCA experience cognitive deficits in the
absence of any injury to the central nervous system. IQ levels of patients with SCA were
reported to be between 4-7 scaled points lower than that of those without the disease.
Complications of sickle cell anemia can be fatal.
Introduction
Sickle cell anemia is an inherited group of disorders that cause red blood cells to distort
into a disk or sickled shape (Serjeant, 2013). Normal red blood cells which contain hemoglobin,
a substance that transports oxygen through the body, are flexible, disc shaped and flow through
blood vessels with ease. With sickle cell anemia these cells become hard and sticky, obstructing
blood flow (Fingar et al., 2019). During the process of this disease red blood cells break apart,
initiating early cell death, later resulting in healthy red blood cell shortage. Red blood cells are
replaced about every 120 days however sickled cells commonly die in about 15 to 20 days.
Individuals with sickle cell anemia experience pain due to this shortage of healthy red blood cells
once the oxygenated blood flow to vital organs is blocked.
Sickle cell anemia is the most common hemoglobinopathy, with over 100,000 Americans
in the US affected by the genetic disease (Sundd, Gladwin & Novelli, 2018). As a monogenetic,
autosomal recessive disorder that causes complications such as dactylitis, hemolytic anemia and
pain crisis; sickle cell anemia has the potential to increase the risk of bacterial infections, organ
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damage and stroke (Meremikwu & Okomo, 2016). Although typically in areas where malaria is
common, according to the Global Burden of disease study, it was found during a systemic
analysis that 176,000 people each year die from sickle cell disease complications, 3.2 million
people have sickle cell anemia and 43 million people live with the sickle cell trait worldwide
(Sundd, Gladwin & Novelli, 2018). Sickle cell anemia is a lifelong disease and for most people
there is no cure however bone marrow or stem cell transplants have been done with limitations
due to the high risk involved. Disease management has been set in place to sustain the livelihood
of those individuals affected by sickle cell anemia.
Etiology
Sickle cell anemia is an inheritance of the abnormal sickle cell gene genetically
transferred from both parents. The sickle cell trait is an inheritance of the abnormal sickle cell
gene genetically transferred from one parent and a normal gene genetically transferred from the
other parent (Centers for Disease Control and Prevention, 2004). Determination of whether a
patient is a carrier or non-carrier, is gene dependent on the inheritance from their parents. If both
biological parents carry the mutated gene the child has a 1 in 4 chance of inheriting copies of the
sickle cell gene from both parents. Sickle cell disease is a direct consequence when hemoglobin
that typically carries oxygen through the body from the lungs through red blood cells are
disabled due to the misshapen red blood cells, once sickled. (Mayoclinic, 2022)
The cause of sickle cell disease is due to a mutation on the beta subunit globin gene
where there is a single substitution of an amino acid in the sequence; resulting in a poorly soluble
tetramer when deoxygenated (Onimoe & Rotz, 2020). The deoxy form of the polymerized
hemoglobin occurs from this. Abnormal hemoglobin S is produced instead of normal
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hemoglobin A. This substitution occurs in the gene that notifies the body to produce hemoglobin,
the iron rich protein in the red blood cells.
Patients with the sickle cell trait are also carriers of the hemoglobin S gene meaning they
too can pass the disease on to their child. The inheritance of SCA is also possible when one
parent is a carrier of the disease while the other one has it. Typically, individuals with the trait do
not have symptoms as they do not necessarily have the disease themselves however the ability
for them to experience minor symptoms is not unusual. If both biological parents carry the
mutated gene the child has a 1 in 2 chance of inheriting a copy of the sickle cell gene from one
parent, becoming a carrier. There is also 1 in 4 chance that the child will not inherit any mutated
gene, in turn will not be able to pass it on to their child.
Genetics of Sickle Cell Anemia
Genetically the cause of sickle cell disease involves both homozygosity (HbSS) and
heterozygosity (Example: HbC) for rs334 mutations. The sickling form of hemoglobin S, rs334
is the normal adult hemoglobin from of sickle cell disease. Abnormal hemoglobin S, HbS, arose
from the genetic mutation that occurs in the amino acid base substitution on the 6th codon on the
Beta globin chain of hemoglobin on chromosome 11, causing strands of polymerized
hemoglobin. (Williams & Thein, 2018). The genetic disorder, sickle cell anemia, was suggested
to have originated from five individual mutations from Africa, India and the Middle East. In
these mutations the beta S gene underwent DNA polymorphism, where there is a change in the
nucleotide sequence with amino acids GAG to GTG. This single substitution went from a
hydrophilic glutamic acid to hydrophobic valine (Maakaron et al.,). This type of genetic mutation
is a called a single nucleotide polymorphism (SNP) or single nucleotide variation (SNV).
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Sickle cell disease embraces a group of disorders in which pathology results from the
inheritance of the sickle cell gene can also be a double heterozygote. Heterozygosity for sickle
cell anemia can lead to diminished levels of beta globin production such as Beta thalassemia or
other mutations that are precursors of Beta globin structural variants such as HbC (Williams &
Thein, 2018).
The most common genotype at birth is the homozygous allele of the sickle cell (SS)
disease. Common genotypes of SCA are SC, SS, Sickle-beta zero thalassemia’s and sickle-beta
plus thalassemia (Onimoe & Rotz, 2020). Common types of anemia in the United States are
caused by mutations in the HbS gene and the HbC gene as well as the different thalassemia
associated with the blood. Hematologically and clinically, sickle cell Beta thalassemia and sickle
cell disease are severe genotypes (Serjeant, 2013).
There is variation in the the severity and frequency of the complications in both
genotypes. Immigrated people found in the US effected by SCA are commonly found with some
sort of ancestry from Southeast Asian, they typically have the Hb E gene mutation (Braunstein,
2020). The most severe sickle cell type with 60-70% US cases is homozygous HbSS; this type is
a two abnormal hemoglobin “S” gene inheritance from both parents (Centers for Disease Control
and Prevention, 2004). HbSC sickle cell type is where one abnormal hemoglobin “S” gene is
inherited from one parent and one abnormal hemoglobin “C” gene is inherited from another
parent; this form of SCA is typically milder. In rare cases of SCA patients have type HbSD,
HbSE or HbSO where they have one abnormal hemoglobin “S” gene inheritance and one
abnormal O, E or D gene from their parents. There rare types of SCA vary in severity. Common
types of anemia in the United States are caused by mutations in the Hb S gene and the HbC gene
as well as the different thalassemia associated with the blood (Braunstein, 2020). Individuals
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inherit the HbS beta thalassemia type of SCA by one abnormal hemoglobin “S” gene and one
beta thalassemia gene (Centers for Disease Control and Prevention, 2004). The “zero” HbS beta
gene is a severe form of HbS beta thalassemia in SCA while “plus” HbS beta is the milder form
of HbS beta thalassemia in SCA (Centers for Disease Control and Prevention, 2004).
In the sickle cell trait, HbAS gene, there is one hemoglobin S gene inheritance and one
normal hemoglobin A gene. This is the gene where there is typically no sign of disease (Centers
for Disease Control and Prevention, 2004). Health issues or symptoms commonly occur with
stress to the body, this can be through exercise or from dehydration. Parents only pass the
abnormal hemoglobin S gene to their child. The quantitative HbF trait is the gene that impacts
the severity of sickle cell anemia (Williams & Thein, 2018). The BCL11A gene which
suppresses HbF production in adults but increases levels of fetal hemoglobin use gene therapy to
reduce severity in the disease (Williams & Thein, 2018).
Diagnosis
Sickle cell disease can be easily diagnosed in DNA through a blood test. Although the
main form of diagnose of SCA, if blood test results are not clear enough, genetic screening can
be done. (Centers for Disease Control and Prevention, 2004). These test can also tell whether you
carry the full gene or the trait and how many copies of the sickle cell gene an individual has.
With access to more advanced technology, diagnosis of sickle cell disease for women
pregnant in the United States can be done as early as in utero while a mother is pregnant The
sickle cell trait is an inheritance of the abnormal sickle cell gene genetically transferred from one
parent and a normal gene genetically transferred from the other parent (Centers for Disease
Control and Prevention, 2004). During in utero diagnosis of sickle disease from no earlier than 8
to 10 weeks, testing can be done one of two ways; one way is amniocentesis where a sample of
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the amniotic fluid that the fetus is encapsulated in is tested. Another way in utero diagnosis is
completed is through a sample of the placenta; this is called Chronic villus sampling where both
genetic and chromosomal abnormalities can be tested (Singh et al., 2015). Early diagnosis of
SCA is emphasized as children are at higher risk of infection.
Sickle cell diagnostic testing vary depending on the patients age. Diagnosis of SCA can
be done in newborns through neonatal screenings and in young adults or older, the diagnosis can
occur through peripheral blood smear, hepatobiliary function test and hemoglobin solubility test.
Compared to in utero screening, newborn diagnosis can predict the severity of the sickle cell
anemia (Maakaron et al.,2021).
Diagnosis can be done through high performance liquid chromatography, capillary
electrophoresis, isoelectric focusing and gel-based electrophoresis (Williams & Thein, 2018).
Most of those methods of diagnosis are used when performing blood test. Sickle cell disease can
also be diagnosed through imaging studies such as MRIs, CT scans and radiography. When
issues with diagnosis arose for reasons such as lowered sensitivity, different approaches
involving next-generation sequencing analysis and tandem mass spectrometry were developed
(Williams & Thein, 2018). Additionally, sickle cell anemia can be diagnosed through
transcranial near-infrared spectroscopy or cerebral oximetry, echocardiography and transcranial
Doppler ultrasonography as well. (Maakaron et al.,2021).
Abdominal ultrasonography for SCA diagnosis is typically used to eliminate an ectopic
pregnancy or complications such as cholelithiasis and cholecystitis (Maakaron et al.,2021).
Pulmonary hypertension can be recognized through echocardiography in individuals with sickle
cell anemia. Through transcranial near-infrared spectroscopy or cerebral oximetry, effected
children have the opportunity to be screened for cerebral venous oxygen saturation. Transcranial
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Doppler ultrasonography is a screening used for children with SCA that have a greater risk of
stroke. Although MRIs are typically used for bone marrow detection they can be utilized to
monitor changes of acute or chronic infarctions as well as osteonecrosis, marrow hyperplasia and
osteomyelitis. Radiography, as a form of diagnosis is valued for its detection of respiratory
symptoms. (Maakaron et al., 2021)
Lab testing performed on patients with sickle cell anemia are including but not limited to
hemoglobin electrophoresis, peripheral blood smear, serum electrolytes, hemoglobin solubility
testing and blood cultures. Kidney function of individuals affected by this disease can be
evaluated through urinalysis, BUN and creatinine testing (Maakaron et al., 2021). Diagnosis of
sickle cell anemia is commonly associated with further health complications making it necessary
to expand testing into other fundamental mechanisms of the human body. Early detection of
sickle cell anemia is beneficial for patients to start managing complications, considering it is
incurable.
Signs & Symptoms
Individuals with sickle cell anemia may experience signs and symptoms as early as 6
months of age. Early signs or symptoms that relate to this disease are severe headaches,
unexplained numbness, confusion, or dizziness. Patients may also experience issues walking or
slurred speech, malaise and fatigue. Paralysis or weakness on one side of the face, arms or legs
are also key indicators or blood pressure issues associated with sickle cell anemia (Mayoclinic,
2022). SCA symptoms can be exacerbated by a few external and internal reasons such viral
infections, localized trauma or fever (Braunstein, 2020). Due to lack of blood circulation patients
may experience dactylitis, which is swelling in the feet and hands (Meremikwu & Okomo,
2016). With a shortage in the healthy red blood cells a delay in puberty or a stunt in growth in
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children and babies may be occur. The blood vessels in the eyes may also be affected by the
sickled cells, causing damage to the retina leading to issues with vision.
When oxygenated blood flow to the vital organs is blocked due to sickle cell disease
causing pain, the individual experiences a “pain” crisis; crisis can also be triggered by
circumstances associated with low blood volume or increased blood acidity (Fingar et al., 2019).
Typical pain crisis triggers involve stress, alcohol, smoking, pregnancy, infections, strenuous
exercise, dehydration, sudden temperature change or other medical conditions. These crises
episodes vary in severity and length of time in each person, it may even progress or diminish
over time (Fingar et al., 2019). The pain individuals experience is aggressive enough to put them
in the hospital once the pain becomes too severe. This significant and common symptom of SCA
may become chronic in some people causing damage to the joint and bones as well as
formulating ulcers.
When symptoms affect the mobility or vision of an individual it is advised to seek
medical attention as soon as possible. An individual should seek a doctor when they experience a
stiff neck, a painful erection for hours, slurred speech, yellowing in the eyes or skin, difficulty
breathing or weakness in the body. It is important to pay special attention to children as they are
prone to infections, typically initiate by fevers that can turn fatal (Mayoclinic, 2022).
Pathophysiology
The pathophysiology of SCA relies on the genetics of endometrial dysfunction, HbS
polymerization, sterile inflammation and vaso-occlusion. The initial approach is to better
understand the biomolecular and biophysical mechanisms of hemoglobin polymerization. The
studies on molecular and cellular mechanisms of sickle cell disease have motivated the evolution
of vaccinations and prophylactic therapies (Sundd, Gladwin & Novelli, 2018). Other
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physiological processes associated with SCA is hemolysis, endometrial dysfunction and blood
vessel occlusion (Williams & Thein, 2018). All of these which can potentially lead to multiorgan
issues.
Vaso-occlusion or cell adhesion is a blood vessel occlusion that can lead to ischemia in
patients with sickle cell disease is the number one cause of “pain” crisis in patients (Sundd,
Gladwin & Novelli, 2018). As a key mechanism that encourage the clinical aspect of sickle cell
anemia, HbS polymerization modifies features of the red blood cells that initiate the obstruction
of blood flow, potentially harming our vital organs. Endometrial dysfunction occurs when
oxidative stress is present in the blood vessels and cell of individuals with SCA.
Sterile inflammation in individuals with SCA is initiated by the release of cytokines
(inflammatory molecules) and the activation of red blood cells. Due to main role inflammations
plays in the pathophysiology of SCA, evidence suggest anti-inflammatory drugs may soon
replace therapies, transplants and transfusions (Conran & Belcher, 2018). Numerous
inflammatory responses are results of complications experienced in SCA; these are including but
are not limited to auto splenectomy, pulmonary hypertension, nephropathy, leg ulcers and acute
chest pain (Conran & Belcher, 2018). The pathophysiology of SCA is contingent upon ones’
genetics.
Sickle Cell Anemia and the Nervous System
Although neuropathies are not common in patients with sickle cell disease, there have
been reports of them occurring in patients with sickle cell disease; specific neuropathies such as
peripheral neuropathy, mental & mandibular nerve neuropathy and mononeuropathy multiplex
are the few commonly associated with the disease (Ballas & Darbari, 2013). It is expected for
individuals with SCA to experience neuropathic pain in the central nervous system due to their
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relations however that is not the case. The few complications associated with SCA and the CNS
are cerebral intracranial hemorrhage, hearing loss, cognitive dysfunction, spinal cord infarction
and cerebral infarction (Ballas & Darbari, 2013).
To avoid further complications, it is advised of individuals with SCA to seek neurological
care early. A preliminary approach for treatment of neurological complications that may arise in
individuals due to SCA is the use of aspirin. Although continued use of aspirin could put a
patient at risk for intracranial hemorrhage, it reduces ischemic activity that is recurrent
(Alroughani et al., 2016). Patients should seek professional medical help for advanced treatments
such as hydroxyurea and red blood cell transfusions. Further neurological complications in SCA
are including but not limited to moyamoya, brain infections, SCA delirium, SCA psychosis and
brain atrophy (Alroughani et al., 2016).
As a frequent symptom in patients with sickle cell anemia, the direct cause of headaches
has yet to be determined. The question still remains whether is it related to stress, the anemia or
circulation. Because of the decrease in blood flow and the constant low state of hemoglobin in
the blood headaches remain common.
Neuropathic and nociceptive pathways have said to be involved in neuropathic pain.
According to Al Jafar in his study nociceptive pain is a result of noxious stimuli activation of
nociceptor sensory receptors. Neuropathic pain is due to damage to the central and peripheral
nervous system or a malfunction in the nervous systems communication (Ballas & Darbari,
2013). The symptoms associated with neuropathic pain is tingling or numbness, the sensation of
pins and needles or hyperalgesia.
Hemorrhagic strokes due to neurologic injury or a brain bleed is also a possible
neurologic symptom of sickle cell anemia. Potentially leading to aneurysms, subarachnoid
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hemorrhage or intra cerebral hemorrhage are associated with the impairment of the coagulation
profile in sickle cell anemia. Ischemic stroke has been reported in about 8 to 11% of SCA cases
involving children (Alroughani et al., 2016). These symptoms due to a minor neurological
dysfunction in the brain include aphasia, cranial nerve palsy, seizures and even a coma. Strokes
are an isolated event and can occur without any warning. Twenty-year-old patients who are
carriers of the hemoglobin HbSS gene type are 11% more likely to have an overt stroke; 24% of
patients with the same gene type would have had an overt stroke by the age of forty-five
(Brandow & Liem, 2022). TIAs or transient ischemic attacks is a neurologic deficit that can last
anywhere from 1 to 24 hours. This infarctive occurrence is typically difficult to be discovered
radiographically so it is commonly diagnoses through symptoms such as seizures and migraine.
TIAs in may appear to resemble muscle spasms in radiographic studies (Alroughani et al., 2016).
Moyamoya or spontaneous occlusion in the arteries according to Al- Jafar and his group,
is a rare neurological condition characterized by cerebral vasculopathy. Commonly found in
patients with sickle cell disease but not limited to those with the trait, moyamoya is a blockage in
the arteries at the base of the brain due to restricted blood flow. Symptoms include typical
neurological signs of complications such as headaches, seizures, paralysis, weakness, cognitive
delays and visual disturbances (Alroughani et al., 2016).
Brain atrophy, characterized by neuron loss due to shrinking of the brain is a serious
complication experienced by patients with sickle cell disease. Damaged or lost brain cells cannot
be recovered, resulting in permanent trauma of SCA. Symptoms include difficulty speaking, loss
of motor skills, seizures, dementia and comprehension delays (Alroughani et al., 2016).
Delirium, or state of confusion, in sickle cell disease is characterized by conscious
disturbance or cognitive changes that progress over a period of time. Frequently affecting older
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individuals with SCA, delirium is common in 1 to 10 patients already hospitalized by SCA.
Psychosis, associated with losing touch with reality is a neurological complication found in SCA
patients as well. Because of the sickling and physiological processes affiliated with this disease,
psychosis causes complications or isolation in the brain tissue. Psychosis is diagnoses by
hallucinations or the act of feeling, hearing or seeing things that are not present (Alroughani et
al., 2016).
Morbidity in sickle cell disease individuals is significantly affected by silent cerebral
infarcts and overt strokes. The diagnosis of both an overt stroke and silent cerebral infarct is
tested by an MRI; it is confirmed by the presence of acute infarct. Large arteries, intracranial
internal carotid arteries and middle cerebral arteries are involved in overt strokes; while the
penetrating arteries are involved in silent cerebral infarction (Brandow & Liem, 2022). Infarction
in patients with SCA are often experienced in the deep white matter or cortex of the brain
compared to infarctions occurring in patients without SCA who experience them in the brains
stem, thalamus and rarely the cortex. By 18 years old 39% of individuals with SCA will have
cerebral infarcts and 50% by 30 years old will have cerebral infarcts (Brandow & Liem, 2022).
Women and adults are more at risk of silent cerebral infarction compared to young adults. Major
neurocognitive impairments are necessary in individuals after experiencing an infarctive stroke.
Each silent cerebral infarction an individual experience as a result of SCA, they jeopardize their
neurocognitive outcomes. It is possible for patients with SCA to be at risk of cognitive
impairment in the absence of silent cerebral infarction which has the potential to become worse
as they age, affect their life quality
There has been evidence found of neurobehavioral and cognitive deficits in patients with
SCA even though they have not experienced any cerebral accidents; causing researchers to
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believe there are cellular mechanisms going undetected. According to resent studies, patients
experiencing different chronic hematological diseases are 20% less likely to express poor
educational attainment, depression or anxiety than in those individuals who have SCA (Hardy et
al., 2018). It was also suggested that neurobehavioral complications and cognitive impairments
observed in patients with sickle cell disease could be due to both the chronicity and pain of the
disease (Hardy et al., 2018). Studies on cognitive activity provide evidence that individuals with
SCA experience cognitive deficits in the absence of any injury to the CNS. Through the results,
it has been suggested that slower processing time is in direct relation to white matter integrity
loss. IQ levels of patients with SCA were reported to be between 4-7 scaled points lower than
that of those without the disease (Stotesbury et al., 2018). Adults and children with sickle cell
anemia have been found to have lower cognitive scores on test and are susceptible to have lower
academic attainment. Findings such as these suggest that sickle cell anemia may directly relate to
cognitive impairment in patients that experience vessel occlusion, strokes and metabolic
inflammation. Current evidence suggests that 45-year-old adults and older with SCT (also the
same has having SCA) are at risk of developing cognitive impairments as they age, reducing
normal cognitive function (Cahill et al., 2019). Cognitive functions are assessed by memory,
executive and learning function scores that test longitudinal changes and global cognitive activity
in the brain (Cahill et al., 2019). Damage to the CNS through strokes, cognitive impairment and
silent cerebral infracts are typically the most permanent trauma of SCA. Between 10 to 20% of
adults 40 years or older with the homozygous or heterozygous hemoglobin SS gene have
experienced a cerebrovascular incident at some point (DeBaun et al., 2020).
Although there are few, the complications associated with sickle cell anemia and the
central nervous system such as the specific neuropathies, cognitive dysfunction, cerebral
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intracranial hemorrhage, hearing loss, spinal cord infarction and cerebral infarction can be fatal.
SCA can affect the CNS and blood flow due to limited circulation in the blood vessels reducing
oxygen in the brain and other parts of the body. The use of certain over the counter medication
has been advised for continued use to reduce recurrent ischemic activity, all risk considered.
Neurological care in early sickle cell anemia diagnosis has also been advised to seek in efforts to
avoid further complications, Theses further neurological complications in SCA are including but
not limited to brain atrophy, brain infections, moyamoya, SCA delirium and SCA psychosis.
With little evidence to support the claim that SCA causes severe headaches this symptom
continues to taunt patients, it has considered to be a complication due to the hemorrhaging and
low blood flow circulation. Neuropathic pain is not extremely common in SCA however when
apparent neuropathic and nociceptive pathways ae involved. A hemorrhagic stroke is a more
common neurologic symptom of sickle cell anemia. Artery blockage in moyamoya may after
individual with both sickle cell anemia and the trait. Brain atrophy, a more dangerous
neurological complication of SCA may result in permanent damage. Cognitive changes and
conscious disturbance in sickle cell disease progress with age and time. Cognitive attainment for
carriers of SCA experience a decrease in memory and processing further lowering their IQ
compared to others who are not carriers. These finding had a direct correlation to patients with
SCA with increased insecurities, anxiety and depression. Sickle cell anemia does not have a
direct cure and damage to the central nervous system is permanent. Research efforts are taking
place in treatment and preventions options for SCA, more efforts could be placed in
complications that arise in the CNS due to SCA. For example, care management in cases that
result in neuropathy or methods on improving already damaged cognitive abilities or methods to
stabilize cognitive processing to avoid further damage.
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Sickle Call and Race
Sickle cell anemia affects 1 in every 350 black children (Onimoe & Rotz, 2020). Each
year over 220,000 babies are born with sickle cell disease in Africa, affecting 1 in 2000 live
births, killing most by the tender age of 5 (Meremikwu & Okomo, 2016). In the Hispanic culture
SCA affects 1 in every 16,300 American births. African Americans were reported to have the
highest amount of inpatient hospital stays with check ins reported at 87.5% compared to
Caucasians with 1.7% and Hispanics with 3.9% of check ins for patients with SCA. It was
recorded in 2016 that approximately 90 percent of sickle cell disease related stays were of black
individuals (Fingar et al., 2019).
1 in every 3 adults are carriers of this disease in sub-Saharan African, often affecting
those of the Mediterranean, sub-Saharan, Caribbean, Asian and Indian decent (Meremikwu &
Okomo, 2016). William and Thein found recently that SCA is a significant contributor to health
issues in multiple regions beyond its original geographic origins through global population
migration. This include Brazil, the United Kingdom, the United States, France the Caribbean
Islands and parts of European countries. Sickle cell anemia is also found in some parts of
Southern Turkey, Greece and Sicily, coincidentally these areas are prevalent with malaria.
With higher frequencies in equatorial Africa and low frequencies in the north and south,
the sickle cell trait is extensive throughout the continent. The sickle trait alone affects almost 10
to 30 percent of Africa’s population and is commonly found in areas where malaria is prevalent
(Meremikwu & Okomo, 2016). Reaching its highest presence in the eastern Province, the sickle
cell trait is widespread in Saudi Arabia. According to Serjeant, the trait often occurs in central
India amongst the tribal peoples with a minor group south of the country. This central group
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consist of Western Odisha, Maharastra, Chhattisgarh, Madhya Pradesh and southeastern Gujarat
while the southern group involves Kerala and northern Tamil Nada.
Sickle cell disease is predominantly homozygous, SS in India and Arabian Gulf. High
frequencies of rs334 were found in parts of India, the Mediterranean basin, the Middle East and
sub-Saharan Africa with 10 to 20% rates.
Sickle Cell and Age
The life expectancy of individuals with sickle cell anemia is about two decades shorter in
adults compared to children and young adults. The median age of death for individuals with SCA
is 42 years old for women and about 48 years old for men; keeping the life expectancy on
average between 42-47 years old (Meremikwu & Okomo, 2016). In severe cases, the average life
span for an individual with SCA related issues is 30 years old. In Africa 50% of children die
before they make it to their first birthday (Meremikwu & Okomo, 2016). In England about 350
babies are born each year with sickle cell anemia.
Symptoms of sickle cell disease tend to worsen between the ages of 18-34; there was a
recorded 37.2% diagnosis for inpatient hospital visits in the early 2000s. An average of 30%
patients aged 40 years old but younger than 65 years old, experience compromising cardiac
function. (Fingar et al., 2019).
The most inpatient stays belonged to the young adult age group with a 41% increase from
2000-2014 with an increase in stays for adults 64 and older (Fingar et al., 2019). Between 2000 –
2016 inpatient stays involving sickle cell disease for patients 45 years or older more than
doubled in SCA diagnosis admission rate (Table 1). (Michas, 2019).
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Number of Patient Admission Rate by Age Per Year
2000

2004

2008

2012

2016

1 Years Old +

26,900

28,800

24,800

27,500

25,700

18 Years Old +

46,300

50,100

50,000

63,100

67,900

35 Years Old +

19,200

17,400

15,700

18,000

19,700

45 Years Old +

8,000

11,400

13,100

14,900

17,700

65 Years Old +

1,000

1,400

1,300

2,100

2,900

Table 1: This table depicts the number amount of stays recorded for patients by age diagnosed with sickle cell
disease between the year 2000 to 2016. (Michas, 2019).

Strokes or other fatal symptoms of sickle cell anemia may be experienced as early as 6
years old with more problems beginning to emerge by early adolescence. Common symptoms
can prevail as early as 5 months old and may begin to plateau around the age of 65 and older
(Figure 1) (Michas, 2019). For adults from the age of 18 to 44, a record high hospital
readmission rate was recognized compared to other age groups (Fingar et al., 2019).
72,000

SCA Diagnosis Admission Rate

64,000
56,000
48,000

40,000
32,000
24,000
16,000
8,000
0
2000

2004

2008

2012

2016

Year
1 Years Old +

18 Years Old +

35 Years Old +

45 Years Old +

65 Years Ol +

18

Figure 1: Admission rate of patients diagnosed with sickle cell disease. This figure depicts the recorded amount of
hospital admission rates for patients of all ages diagnosed with sickle cell disease between the year 2000 to 2016.
(Michas, 2019).

Complications
Several complications may arise with those infected by SCA, affecting areas or organs of
the body that people did not think would be affected, see table 2. These are included but are not
limited to gallstones, kidney disease, splenic sequestration and blindness. A few other
complications of sickle cell anemia are chronic anemia, leg ulcers, retinopathy, pain in the bones
and avascular necrosis to name a few (Onimoe & Rotz, 2020).
Sickle cell anemia may also cause pregnancy complications increasing blood clots or
high blood pressure in soon to be mothers; or priapism in men. Priapism causes erections in men
with sickle cell disease that are long lasting resulting in pain due to the blockage of blood vessels
in the penis (Mayoclinic, 2022).
Due to its relation to blood pressure, sickle cell disease may also cause pulmonary
hypertension or deep vein thrombosis in patients (Mayoclinic, 2022). Vaso-occlusion, a blood
vessel occlusion that can lead to ischemia in patients with sickle cell disease is the number one
cause of pain crisis in patients (Sundd, Gladwin & Novelli, 2018). SCA complications in the
central nervous system may be managed in the same way strokes can. Individuals may seek
lifelong chronic transfusions.
Treatment, Care Management and Prevention
There are a few management strategies from vitamin intake to bone marrow or stem cell
transplant to subdue pain and complications of sickle cell anemia (Onimoe & Rotz, 2020).
Treatment is necessary to reduce mortality and morbidity in patients with sickle cell disease. A
few pharmaceutical inventions such as pneumococcal vaccines, penicillin prophylaxis,
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hydroxyurea and malaria chemoprophylaxis have been developed to help prevent sickle cell
crisis (Meremikwu & Okomo, 2016).
Home care treatment is a for of care management for less aggressing cases of SCA. Over
the counter medications such as aspirin, ibuprofen, alive or Tylenol can be taken to manage pain
and minor symptoms. Other ways to manage mild symptoms at home include rest, heating pads,
warm baths, staying hydrated and massages.
In cases of extreme pain or symptoms where at home care management is not working
seeking a doctor is advised. During this hospital visit a provider may check for infection, fever,
crisis triggers or dehydration. For pain patients may be prescribed more aggressive pain
medication such as oxycodone, codeine or other nonsteroidal anti-inflammatory drugs depending
on their level of pain. In severe cases, providers may prescribe meperidine, hydromorphone or
morphine; where patients are in a fatal state of a crisis blood transfusions may be required.
Although a crisis or sickle cell anemia itself is not preventable, there are certain ways to
reduce the risk of having a crisis. It is always highly recommended to take all vitamins and
medication prescribed by the doctor, avoid smoking, avoid drinking, avoid infection by staying
clean, manage stress, stay hydrated and stay warm in low temperature weather.
Four possible pharmaceutical inventions for crisis prevention have been administered in
the United States. Pneumococcal vaccines are used in infants starting from the age of 2 months
old and recommended to be used routinely. There are two types of pneumococcal vaccines,
pneumococcal conjugate vaccines and polyvalent polysaccharide pneumococcal vaccines
(Meremikwu & Okomo, 2016). Polyvalent polysaccharide pneumococcal vaccines are
specifically recommended to be used in children 2 year and older. Penicillin prophylaxis is a
method used in children with SCA that is five years or older to reduce infection as they are more
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susceptible and this will aid in decreasing the bacterium Meremikwu & Okomo, 2016).
Hydroxyurea has been shown to reduce a few complications brought on by SCA however it has
yet to be confirmed if there are long term effects of the drug. Malaria chemoprophylaxis, the
regimen involving the consumptions of a medication before, during and after traveling to an area
with high malaria rates. Although considered to be useful, malaria chemoprophylaxis is still
being evaluated on its effects and benefits of consumption (Meremikwu & Okomo, 2016).
Strategies on therapeutic treatment has been sought out to target sickle cell disease. The
initial approach is to better understand the biomolecular and biophysical mechanisms of
hemoglobin polymerization. The studies on molecular and cellular mechanisms of sickle cell
disease have motivated the evolution of vaccinations and prophylactic therapies (Sundd, Gladwin
& Novelli, 2018).
Medical Care
As a neglected disease, sickle cell anemia is a costly, long term health condition that
commonly affects Hispanic and African American people (Lee et al., 2019). The low-income
community makes up approximately 92.5% of inpatient hospital visits for patients diagnosed
with sickle cell anemia and its complications. About 31.4% of these patients went to hospitals in
rural areas, 52.4% of the patients went to hospitals in metropolitan areas and the remote hospitals
took in about 16.2% of these patients (Fingar et al., 2019). It was discovered that the majority of
sickle cell anemia related stays for individuals in the metro community actually transpired in
metro area hospitals; whereas 50% of sickle cell anemia related stays for individuals from rural
communities transpired in metro area hospitals as well.
Limited access to proper medical care is a common challenge people with sickle cell
anemia encounter (Lee et al., 2019). Comprehensive care for those infected by this disease is
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scarce due to the lack of expertise in health care providers today. Rural communities with lowincome areas experience the backlash of improper care as their resources are limited. People in
these areas typically depend on Medicaid and Medicare to cover their medical care, with
specialized health care limited on coverage with these plans; there is not sufficient care being
provided (Lee et al., 2019). With these limitations individuals with sickle cell disease result to
visiting hospitals and emergency departments. Because SCA is both a socially and medically
complex illness that continues to affect carriers of the gene mutation throughout their lives, it is
imperative adult care is prioritized (Kanter et al.,2020). Because of the limitations for health care
in most of the United states, there is an increase of early mortality in patients, care utilization and
disjointed care delivery. There is need for more specialized health care providers in hematology
to apply adult care to individuals with SCA (Kanter et al.,2020).
In 2014 alone there was a recorded 250,000 hospital visits of patients with sickle cell
anemia; with a readmission rate of 80% between a 14 – 30-day turn around compared to a 12.5%
non-disease related readmission rate (Fingar et al., 2019). Most of those readmitted were
originally admitted through the emergency department compared to normal admission.
According to a statistical research on inpatient hospital stays involving sickle cell disease,
134,000 disease related stays were recorded in 2016 with three-fourths plus of these stays
involving pain crisis (Fingar et al., 2019). Inpatient hospital stays averaged about 5 days in
length for adults and 4 days for children, with a discharge rate that was four times higher than
non-disease related stays (Fingar et al., 2019). Most of the hospital emergency room intakes
recorded were of patients with sickle cell disease compared to those without the disease.
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Conclusion
Worldwide, 176,000 people each year die from sickle cell disease complications, 3.2 million
people have sickle cell anemia and 43 million people live with the sickle cell trait. The cause of
sickle cell anemia is due to a single substitution from glutamic acid to valine. As a lifelong
disease, sickle cell anemia has no cure however bone marrow or stem cell transplants have been
considered with limitations because of the high risk involved. If both biological parents carry the
mutated gene, a child has a 1 in 4 chance of inheriting copies of the sickle cell gene from both
parents. Because sickle cell anemia is commonly associated with further health complications
further investigation into fundamental mechanisms of the human body have been initiated. To
start managing complications, it is advised that individual get annual check-ups for early
detection of sickle cell anemia. Due to lack of blood circulation patients may experience
dactylitis or headaches. SCA symptoms can be exacerbated by a few external and internal
reasons such viral infections, localized trauma or fever. Further physiological processes
associated with SCA is blood vessel occlusion, endometrial dysfunction and hemolysis. The
median age of death for individuals with SCA is 42 years old for women and about 48 years old
for men; keeping the life expectancy. To reduce mortality and morbidity in patients with sickle
cell disease treatment is recommended. With limited access to proper medical care, people with
sickle cell anemia struggle. To avoid further complications, it is advised patients seek
neurological care. Adults and children with sickle cell anemia have been found to have lower
cognitive scores on test and are susceptible to have lower academic attainment. These findings
suggest that sickle cell anemia is directly related to cognitive impairment in patients.
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Sickle Cell Anemia Complications
Bone Tissue SCA may cause avascular necrosis due to
Hand-Feet Swelling due to blood flow blockage in the blood vessels, commonly found in
toddlers and infants
Kidneys
Due to reduced blood flow and lack of oxygen loss of function occurs,
affecting filtration of waste
Legs
In combination of infection and inflammation ulcers may become present due
to poor circulation in the blood vessels
Liver
SCA increase complications such as gallstones, cholangiopathy and viral
hepatitis
Lungs
Life threatening complications may occur due to blood vessel blockage or
infection, causing breathing issues
Spleen
SCA may cause enlargement due to an excessive amount of trapped sickled
cells
Eyes
Vaso-occlusion of the small vessels may cause blindness
Bones
When blood does not reach the bone causing joints to narrow and to possibly
collapse
Heart
SCA can increase the risk of pulmonary hypertension affecting the lungs as
well. It causes tricuspid valve regurgitation and ventricle dilation
Brain
SCA can increase the risk of silent cerebral infarctions or seizures. Causing
cognitive dysfunction and memory attainment.
Penis
SCA may cause extended, painful erections in men due to blood flow blockage
in the blood vessels
Pregnancy Women may experience blood clots and high blood pressure , increasing the
risk of a miscarriage or still birth
Table 2: This table provides minor details on where in the body sickle cell anemia may cause complications and
how. (Centers for Disease Control and Prevention, 2004) (Mayoclinic, 2022) (Maakaron et al., 2021)
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